Who Generates Higher Gross Profit? AstraZeneca PLC or Bio-Techne Corporation

AstraZeneca vs. Bio-Techne: A Decade of Gross Profit Comparison

In the competitive landscape of the pharmaceutical and biotechnology sectors, AstraZeneca PLC and Bio-Techne Corporation have showcased distinct trajectories in gross profit over the past decade. From 2014 to 2023, AstraZeneca consistently outperformed Bio-Techne, with gross profits peaking at approximately $37.8 billion in 2023, marking an impressive growth of nearly 87% from 2014. In contrast, Bio-Techne's gross profit, while steadily increasing, reached around $770 million in 2023, reflecting a growth of over 200% from its 2014 figures. This stark contrast highlights AstraZeneca's dominant market position, yet underscores Bio-Techne's rapid growth in a niche market. The data for 2024 remains incomplete, leaving room for speculation on future trends. As these companies continue to innovate, their financial trajectories will be crucial for investors and industry analysts alike.